Login / Signup

Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.

Alejandro Piscoya RiveraAngela Parra Del RiegoRenato Cerna-ViacavaJonathon RoccoYuani M RomanAngel A EscobedoVinay PasupuletiC Michael WhiteAdrian V Hernández
Published in: PloS one (2022)
In comparison to SOC or placebo, TCZ reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in RCTs in hospitalized COVID-19 patients. Other clinical outcomes were not significantly impacted. TCZ did not have effect on AEs, except a significant increased neutropenia risk in RCTs. TCZ has a potential role in the treatment of hospitalized COVID-19 patients.
Keyphrases
  • mechanical ventilation
  • sars cov
  • intensive care unit
  • acute respiratory distress syndrome
  • rheumatoid arthritis
  • randomized controlled trial
  • clinical trial
  • combination therapy
  • replacement therapy